*Review* **Current Advances in Pediatric Onset Multiple Sclerosis**

#### **Kristen S. Fisher 1, Fernando X. Cuascut 2, Victor M. Rivera 2 and George J. Hutton 2,\***


Received: 10 March 2020; Accepted: 26 March 2020; Published: 28 March 2020

**Abstract:** Multiple sclerosis (MS) is an autoimmune inflammatory disease affecting the central nervous system leading to demyelination. MS in the pediatric population is rare, but has been shown to lead to significant disability over the duration of the disease. As we have learned more about pediatric MS, there has been a development of improved diagnostic criteria leading to earlier diagnosis, earlier initiation of disease-modifying therapies (DMT), and an increasing number of DMT used in the treatment of pediatric MS. Over time, treatment with DMT has trended towards the initiation of higher efficacy treatment at time of diagnosis to help prevent further disease progression and accrual of disability over time, and there is evidence in current literature that supports this change in treatment patterns. In this review, we discuss the current knowledge in diagnosis, treatment, and clinical outcomes in pediatric MS.

**Keywords:** multiple sclerosis; pediatric multiple sclerosis; neuroimmunology; demyelinating disease; pediatric neurology; child neurology
